Table 2.
Effect of median time-dependent endpoints (TDEs) on median overall survival (OS) estimated from a multivariate censored normal regression, by type of TDE
| Covariables | β | SE | P | 95% CI |
|---|---|---|---|---|
| Median TDE, months |
2.45 |
0.38 |
< 0.0001 |
1.71 ; 3.20 |
| Females,% |
0.05 |
0.24 |
0.83 |
− 0.42 ; 0.52 |
| Median age, years |
0.59 |
0.38 |
0.12 |
− 0.16 ; 1.34 |
| Year of publication |
0.24 |
0.32 |
0.46 |
− 0.39 ; 0.87 |
| Relapsed, refractory, or advanced MM |
14.24 |
7.60 |
0.06 |
− 0.66 ; 29.14 |
| Mixed or not reported type MM |
6.95 |
5.02 |
0.17 |
− 2.89 ; 16.78 |
| TDE (time to progression) |
5.95 |
4.16 |
0.15 |
− 2.21 ; 14.11 |
| TDE (event-free survival) |
− 3.51 |
4.03 |
0.38 |
− 11.42 ; 4.40 |
| Treatment including Thal, Bort, or Len | − 5.98 | 6.08 | 0.33 | − 17.89 ; 5.94 |
Note: Includes 163 uncensored observations and 67 right-censored observations. The constant of the model was suppressed due to non-significance.
Abbreviations: β Regression coefficient, Bort Bortezomib, CI Confidence interval Len Lenalidomide, MM, Multiple myeloma, SE, Standard error, Thal Thalidomide.